tislelizumab
beigene
[]
tislelizumab plus chemotherapy may be a new first-line treatment option for patients with pd-l1-positive, advanced gastric or gej cancer. presented #gi23. #stcsm 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.